Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanistic Study of Otilimab + MTX in Active RA
NCT02799472Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2016
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing GSK3196165 + MTX with Placebo + MTX (2 arms). Primary endpoints: Change From Baseline in Target Engagement Biomarkers- Soluble Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) Complexed to GSK3196165 at 22 weeks, Change From Baseline in Predictive Biomarkers: 14-3-3 ETA Protein, S100 Calcium Binding Protein (CBP) A8 and A9 at 22 weeks and 8 more. Started Jun 2016; status: completed.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02799472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02799472.